6 recruiting, 1 active not recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 6, Active not recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow ARQ531: new trials by email Literature Review of ARQ531 trials Research Report on ARQ531
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 27 | 2025-01-22 | 2026-03-13 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Nemtabrutinib - Hematologic Malignancies, Waldenstroms Macroglobulinaemia | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 490 | 2021-04-05 | 2026-11-17 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) Nemtabrutinib - Lymphoma, B-Cell, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 190 | 2017-06-26 | 2026-06-12 |
Leukemia, Lymphocytic, Chronic, B-Cell (4) · Hematologic Neoplasms (2) · Leukemia, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Waldenstrom Macroglobulinemia (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Immune System Diseases (1)
City of Hope Medical Center (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Fred Hutchinson Cancer Center (1) · Jennifer Woyach (1) · Merck Sharp & Dohme LLC (1) · Roswell Park Cancer Institute (1)
United States (7) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Ireland (1) · Israel (1) · Italy (1) · Poland (1)
Alexey V Danilov (1) · Geoffrey Shouse (1) · Jennifer A Woyach, MD (1) · Jennifer Huang, MD, PhD (1) · Matthew J Cortese (1)
P30CA033572 (2), 2023 (1)